Dr. Daniel J Renouf, MD
Claim this profileBC Cancer - Vancouver
Studies Breast Cancer
Studies Pancreatic Cancer
5 reported clinical trials
12 drugs studied
Area of expertise
1Breast Cancer
Stage IV
PR positive
HER2 negative
2Pancreatic Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Daniel J Renouf, MD is currently running
Atezolizumab
for Cancer
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.
Recruiting1 award Phase 210 criteria
Perioperative Chemotherapy
for Pancreatic Cancer
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting4 awards Phase 318 criteria
More about Daniel J Renouf, MD
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Daniel J Renouf, MD has experience with
- CFI-402257
- BMS-986253
- Ipilimumab
- Nivolumab
- SLC-0111
- Gemcitabine Injection
Breakdown of trials Daniel J Renouf, MD has run
Pancreatic Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel J Renouf, MD specialize in?
Daniel J Renouf, MD focuses on Breast Cancer and Pancreatic Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are PR positive.
Is Daniel J Renouf, MD currently recruiting for clinical trials?
Yes, Daniel J Renouf, MD is currently recruiting for 2 clinical trials in Vancouver British Columbia. If you're interested in participating, you should apply.
Are there any treatments that Daniel J Renouf, MD has studied deeply?
Yes, Daniel J Renouf, MD has studied treatments such as CFI-402257, BMS-986253, Ipilimumab.
What is the best way to schedule an appointment with Daniel J Renouf, MD?
Apply for one of the trials that Daniel J Renouf, MD is conducting.
What is the office address of Daniel J Renouf, MD?
The office of Daniel J Renouf, MD is located at: BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6 Canada. This is the address for their practice at the BC Cancer - Vancouver.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.